Prognosis
Oxford-Astra Covid Vaccine Review to Start in Europe
- Vaccine is first Covid candidate to undergo EU process
- ‘Rolling review’ means final clearance could be sought faster
This article is for subscribers only.
European regulators started an accelerated review of a Covid-19 vaccine front-runner from the University of Oxford and AstraZeneca Plc in a sign the shot could be the first to seek approval in the region.
The European Medicines Agency announced the start of the so-called “rolling review,” confirming a Bloomberg report from Wednesday. Such assessments are typically used in health emergencies to allow regulators to see clinical trial data while the development is ongoing to speed up approvals.